Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of HA35 in Patients With Alcoholic Liver Disease
NCT05018481Phase 1Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Sep 2022
- Primary completion
- Oct 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial in alcoholic hepatitis (AH) comparing HA35 Placebo Group with HA35 Treatment Group (2 arms). Primary endpoint: Percent change of skeletal muscle mass at 90 days. Started Sep 2022; status: recruiting.
02
Drugs
ha35
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT05018481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018481.